Blueprints notes and cases pharmacology

olueprints Notes & Cases Pharmacology this is for non-commercial usage by Russian-speakers only! if you are not a Russian-speaker deLete this file immediat e Ly ! PYCCKHX nonb3OBaTe llel.1 - spa e&.11.1 Y'leHbIX , B oco6eHHOCTH CB060AHOfO, Het 64 GJipizide 64 Glu«)(orticoids, 153 GI~te dehydrogenase (G-6-PO) detiCierq,96, 118 Glyburide 63-64 Gly«fin, 77,1 04 GIY(Qprotein I\bJUla inhibitors, 32- 33 Goiter, 57 Gonorrhea, 107- 108 114 Goserelin, 153 154 Gout, 67, 90-92 G protein, 85 Granisetron 102 Grave'!' dise,",,- 57-58 169 Gynecomastia from antiandrogens 153 154 from dmetidine, 98 from ketO«lnazolf' 13 from spironolactone, 24 Haemophi/us influenzaf' amoxidll in fOf, 106, 174 beta-lactamase inhibitors for, 108 cephalosporiru for, 110 11 I macrolides for, 11 114, 174 rifampin for, 133 tetracycli ne for 116 Half-life, drug 2-4 Haloperidol, 53, 169 Hand-foot syndrome 145 Hashimoto's thyroiditis 59 Hay fever, 73 74 H~es 39-41 See also Migraine analgesic overuse, 168 asthma drugs and, 69 dassificat ion of, 39 d uster 168 fluoroquinolones and t 18 H2-feceptor antagonists and, 98, 173 nifed ipine, 85 tension 39 Heart failure See congestive heart failure Helicobaderpyfor~ 97 98, 114, 11 6, 125, 173 Heparin 31.167 aspirin and 32 Iow-moleculaf-wetght 29, 31 unfractionaled, 29, 31 Hepatitis, 139-140 anti retrovi rals for , 136 erythromycin and, 114 liver transplant for, 160 Hepatocellular carcinoma, 79,139,142 Herpes viruses 128-129, 157 Hip fracture 81 Higamine-rec:eptor antagonists 97- 100 HIVdisease,I29-130 ant iretrovirals 'Of, 135-138 176 interferon for, 140 HMG CoA reductase inhibitors See 5tatins Hodgkin's disease, 142, 144 151-152 Hormonal agents, 153 155 178 Hormone replacement therapy (HRn, 81-82, 172 Hot flashes, 81-82 H1-receptor al'l1agonists forGERO,99-100 for PlIO 97-98 5-HTl antagonists, 101-102 Human herpes virus (HHV) 129 Human immunodeficiency virus See HIV disease Hydrochlor othiazide, 23, 91, 96 Hydrocodone,35 Hydrocortisone, 89, 154, 172 Hydromorphone, 34 36 HydroKydlloroquine.96, 173 5-Hydroxytryptamine-3 re[...]... their constant encouragement and support And to my husband, Ray, for his love, patience, and never-ending faith in me - Katherine Y Yang To my parents Donald and Theodora, and my sister Dena Thank you for your love, support and encouragement To my husband Micheal for all your patience, friendship and love And to my daughter, Riley, for inspiring me to see life in so many new and exciting ways -Larissa... Julia and Jen who kept us organized and on trade I want to thank Kathy and Larissa for organizing and revising the text and tables I would also like to acknowledge the support I receive from my mentors at UCSF and UC Berkeley Gene Washington, Mary Norton, Miriam Kuppermann, Halluft Jamie Robinson Matthew Rabin, and Teh·Wei Hu I also want to thank my parents Bill and Carol, my siblings Ethan and Samara,... meaningful and memorable Students will be leaming not only the why of a principle, but also how it might commonly be seen in practice The books in the BlueprintE Notes & Cases series feature a comprehensive collection of cases that are designed to introduce one or more basic science topics Through these cases, students gain an understanding of the coursework as they leam to: • Think through the cases •... and is mainly hepaticaly eliminated Toeainide is eliminated viii wnjugation and 40% UI'IdwIged in the urine Therapeutit range: Lidocaine =- 1.5-5I1Q1mL Advene reactions: Minor side effects of lidocaine are drowsiness, diuineM, ~sia, and euphoria More serious side effects indude CNS and cardicmscular effects Tocainide and mexiletine both hiM! a high inddeoce of GI side eff~ts (nausea and vomiting) and. .. cirrhosis, and in the elderly Oisopyramide is both hepaticatly and renallydeated Both propafenone and moricizine are mainy hepatically eliminated while fie ... Male: 41 - 53% Female: 3 6-4 6% :5 6% Male: 13. 5-1 7.5 g/dL Female: 12. 0-1 6.0 gldl 450 0-1 1,OOOImml 5 4-6 2% 3-5 % 1- 3% O-j).75% 2 5-3 3% 3-7 % 25. 4-3 4.6 pgleell 3 1- 36% Hbleell 8O-1oo),l.m1 2 5-4 0 seconds... PO (fV) (!w) PO IIV) "'ltv} 2-3 (15 min) 2 4-7 2 1 2- 16 1 2-1 6 1 2-2 4 '1 .-2 5'h-15 No data (5 min) 'h (2 min) (10 min) 6-8 (2) 4-6 ('/ ,-1 ) H 'h 6-8 '" 2 4-4 8 2-4 " '-7 2 1 2- 16 " 20 Case Conclusion According... Therapy-Case Report Drug Therapy-Problems and Exercises Pharmacology (ase Report Pharmacology- Problems and Exercises QV 18.2 Y219b 2004)1 Title: Pharmacology II Title: Blueprints notes and cases